Research led by the University of Southampton into the uptake of the COVID-19 vaccine in Ghana, West Africa has concluded that vaccine hesitancy has seen a small, but significant increase over the last three months. This research is in collaboration with youth-led not-for-profit organisation PACKS Africa.
Researchers are using computer models to simulate COVID-19 infections on a cellular level which allows for virtual trials of drugs and vaccines, opening the possibility of pre-assessment for drug and vaccine efficacy against the virus.
To prepare for the next pandemic and provide a coordinated approach to vaccination across the country, Canada should create Canadian Immunization Services based on the Canadian Blood Services model, authors propose in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.210670.
New research published in Nature Medicine reveals willingness to get a COVID-19 vaccine was considerably higher in developing countries (80% of respondents) than in the United States (65%) and Russia (30%). The study provides one of the first insights into vaccine acceptance and hesitancy in a broad selection of low- and-middle income countries (LMIC), covering over 20,000 survey respondents and bringing together researchers from over 30 institutions.
Vaccine negativity and reluctance is not a recent phenomenon but, to date, little research has been done to explore the dominance of negative vaccine-related information.
Washington, DC / New Delhi, India - Researchers at CDDEP recently published 'Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush' where they evaluated the performance of India's Mission Indradhanush (MI) child vaccination campaign -- a periodic intensification of the routine immunization program.
A new protein-based vaccine candidate combined with a potent adjuvant provided effective protection against SARS-CoV-2 when tested in animals, suggesting that the combination could add one more promising COVID-19 vaccine to the list of candidates for human use.
Combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries. Results from the study, which applied lessons learned from the hepatitis b vaccine platform technology, are published online today in Science Immunology.
Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.
What The Study Did: This community-engaged qualitative study describing Black and Latinx participants' experiences during the COVID-19 pandemic found that fear, illness and loss experienced during the pandemic motivated information seeking and mitigation behaviors, while vaccine skepticism was high, as was the demand for clearer information.